Human allogeneic AB0/Rh-identical umbilical cord blood cells in the treatment of juvenile patients with cerebral palsy

Romanov, Yu. A.; Tarakanov, Oleg P.; Радаев, С. М.; Dugina, T. N.; Ryaskina, S. S.; Darevskaya, Anna N.; Morozova, Yana V.; Khachatryan, W. А.; Lebedev, Konstantin E.; Zotova, Nelli S.; Burkova, A S; Сухих, Г. Т.; Смирнов, В. Н.

doi:10.1016/j.jcyt.2015.02.010

Cited by 52 publications

(34 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The dose‐escalation trial of UCB‐MSCs for BPD did not find evidence of dose‐dependent toxicity, but, interestingly, a trend toward greater benefit with the lower dose was observed (a similar inverse relationship was seen in the adult POSEIDON trial of BM‐MSCs for myocardial infarction ). In contrast, administration of UC‐MSCs for cerebral palsy showed a significant positive correlation between number of doses of UC‐MSCs and likelihood of experiencing improvement . Finally, the meta‐analysis of MSC therapy for acute GvHD did not find response to be dose‐dependent .…”

Section: Clinical Studies Of Msc Therapymentioning

confidence: 83%

“…No further complications arose over a 6‐month follow‐up period. An efficacy case series of 80 patients found that allogeneic, ABO/Rh‐matched, HLA‐mismatched UC‐MSCs administered intravenously resulted in 69% of patients improving muscle tone, strength, speech, memory, attention, or cognition in a dose‐dependent manner, with no worsening of symptoms . No treatment‐related adverse effects were reported, giving further credence to the possibility that the fever and vomiting reported earlier were indeed related to the general anesthesia and intrathecal administration.…”

Section: Clinical Studies Of Msc Therapymentioning

confidence: 90%

See 1 more Smart Citation

Concise Review: Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential Improvements

Nitkin

Bonfield

2016

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) represent a potentially revolutionary therapy for a wide variety of pediatric diseases, but the optimal cell‐based therapeutics for such diversity have not yet been specified. The published clinical trials for pediatric pulmonary, cardiac, orthopedic, endocrine, neurologic, and hematologic diseases provide evidence that MSCs are indeed efficacious, but the significant heterogeneity in therapeutic approaches between studies raises new questions. The purpose of this review is to stimulate new preclinical and clinical trials to investigate these factors. First, we discuss recent clinical trials for pediatric diseases studying MSCs obtained from bone marrow, umbilical cord and umbilical cord blood, placenta, amniotic fluid, and adipose tissue. We then identify factors, some unique to pediatrics, which must be examined to optimize therapeutic efficacy, including route of administration, dose, timing of administration, the role of ex vivo differentiation, cell culture techniques, donor factors, host factors, and the immunologic implications of allogeneic therapy. Finally, we discuss some of the practicalities of bringing cell‐based therapy into the clinic, including regulatory and manufacturing considerations. The aim of this review is to inform future studies seeking to maximize therapeutic efficacy for each disease and for each patient. Stem Cells Translational Medicine 2017;6:539–565

show abstract

Section: Clinical Studies Of Msc Therapymentioning

confidence: 83%

Section: Clinical Studies Of Msc Therapymentioning

confidence: 90%

Concise Review: Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential Improvements

Nitkin

Bonfield

2016

Stem Cells Translational Medicine

View full text Add to dashboard Cite

show abstract

“…Interestingly, they noted that the higher the cell dose given to the patient the better the outcome, suggesting that cell dose is critical for efficacy. This is confirmed by a further study in which administration of greater number of allogeneic UCB cells was associated with better outcome at 36 months [142]. A handful of smaller, non-RCT trials have also added to our knowledge on the efficacy of UCB for treating established CP [142][143][144].…”

Section: Ucb In Clinical Trialsmentioning

confidence: 67%

Umbilical Cord Blood Cells for Perinatal Brain Injury: The Right Cells at the Right Time?

McDonald

Castillo‐Melendez

Penny

et al. 2017

Umbilical Cord Blood Banking for Clinical Application and Regenerative Medicine

View full text Add to dashboard Cite

Cerebral palsy (CP) is the most common cause of physical disability in children. CP currently has no cure and there are only few interventions to prevent the development of disability. There are four principal complications of pregnancy or birth that can damage the developing brain and lead to CP: preterm birth, fetal growth restriction, infection during pregnancy and severe hypoxia-ischemia at birth. Umbilical cord blood (UCB) cells are a very promising therapy for the treatment of CP. While UCB therapy for juveniles with CP is currently being assessed in clinical trials, very little is known about their mechanisms of action or which cells found in umbilical cord blood protect against and/ or repair brain injury. In this chapter, we first explore the complications that can lead to perinatal brain injury. We then discuss the different cell types found in UCB and the specific properties that make each of them individually attractive therapeutic candidates for treatment of perinatal brain injury. While UCB holds much promise as a therapy for CP, it is imperative that more research is conducted to understand how the different cell types found in UCB can protect against brain injury in order to design more effective and targeted therapies.

show abstract

“…There is currently no specific treatment for CP except for rehabilitation training in the clinic (Maclennan et al, ). Since the first transplantation of UCBCs was performed in 1988 (Mreboredo, Diaz, Castro, & Villaescusa, ), UCB‐SC therapy has been widely studied in children with CP, and improved brain cognition and gross motor function have been shown with no serious side effects indicating that the therapy is neuroprotective and safe (Feng et al, ; Huang et al, ; Kang et al, ; Lee et al, ; Min et al, ; Romanov et al, ; Sun et al, ) (Table ). However, current clinical trials focused on UCB‐SC therapy in children with CP have not considered the gestational age partition of the patients, and thus further research is needed regarding children with CP who were born prematurely.…”

Section: Ucb‐sc Therapy In Preterm Brain Injuries and Neurological Sementioning

confidence: 99%

Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges

Peng

Shi

et al. 2019

J of Neuroscience Research

View full text Add to dashboard Cite

Preterm birth and associated brain injury are the primary cause of cerebral palsy and developmental disabilities and are among the most serious global health issues that modern society faces. Current therapy for infants suffering from premature brain injury is still mainly supportive, and there are no effective treatments. Thus there is a pressing need for comparative and translational studies on how to reduce brain injury and to increase regeneration and brain repair in preterm infants. There is strong supporting evidence for the use of umbilical cord blood (UCB)‐derived stem cell therapy for treating preterm brain injury and neurological sequelae. UCB‐derived stem cell therapy is effective in many animal models and has been shown to be feasible in clinical trials. Most of these therapies are still experimental, however. In this review, we focus on recent advances on the efficacy of UCB‐derived stem cell therapy in preterm infants with brain injury, and discuss the potential mechanisms behind their therapeutic effects as well as application strategies for future preclinical and clinical trials.

show abstract

Human allogeneic AB0/Rh-identical umbilical cord blood cells in the treatment of juvenile patients with cerebral palsy

Cited by 52 publications

References 40 publications

Concise Review: Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential Improvements

Concise Review: Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential Improvements

Umbilical Cord Blood Cells for Perinatal Brain Injury: The Right Cells at the Right Time?

Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges

Contact Info

Product

Resources

About